Filariasis and lymphoedema

Parasite Immunology

Volumn 31, Issue 11, 2009, Pages 664-672

  Pfarr, K M ^a   Debrah, A Y ^a,b,c   Specht, S ^a   Hoerauf, A ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

Author keywords

Filariasis; Hydrocele; Lymphedema; TLR; VEGF; Wolbachia

Indexed keywords

ALBENDAZOLE; AMOXICILLIN; CYTOKINE; DIETHYLCARBAMAZINE; DOXYCYCLINE; IMMUNOGLOBULIN G4; IVERMECTIN; TOLL LIKE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3;

BRUGIA MALAYI; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; HYDROCELE; HYPERPLASIA; IMMUNOGENETICS; INNATE IMMUNITY; LYMPHATIC FILARIASIS; LYMPHEDEMA; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; TH1 CELL; TH17 CELL; TH2 CELL; WUCHERERIA BANCROFTI;

ANIMALS; ELEPHANTIASIS, FILARIAL; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; LYMPHATIC VESSELS; LYMPHEDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOLBACHIA;

BRUGIA; WOLBACHIA; WUCHERERIA BANCROFTI;

EID: 70349976424     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01133.x     Document Type: Review

References (76)

1. Karpanen T Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008 3 : 367 397.
2. WHO. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2004 79 : 358 365.
3. Maizels RM, Sartono E, Kurniawan A, Partono F, Selkirk ME Yazdanbakhsh M. T-cell activation and the balance of antibody isotypes in human lymphatic filariasis. Parasitol Today 1995 11 : 50 56.
4. Molyneux DH, Bradley M, Hoerauf A, Kyelem D Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003 19 : 516 522.
5. Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med 2002 347 : 1885 1886.
6. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK Habbema JD. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 2003 188 : 1371 1381.
7. WHO. Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2006 81 : 221 232.
8. Jungmann P, Figueredo-Silva J Dreyer G. Bancroftian lymphadenopathy: a histopathologic study of fifty-eight cases from northeastern Brazil. Am J Trop Med Hyg 1991 45 : 325 331.
9. Ottesen E Weil GJ. Towards a strategic plan for research to support the global programme to eliminate lymphatic filariasis. Am J Trop Med Hyg 2004 71 : 1 2.
10. Mand S, Marfo-Debrekyei Y, Dittrich M, Fischer K, Adjei O Hoerauf A. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003 2 : 3.
11. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006 2 : e92.
12. Brattig NW, Bazzocchi C, Kirschning CJ, et al. The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol 2004 173 : 437 445.
13. Hise AG, Daehnel K, Gillette-Ferguson I, et al. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J Immunol 2007 178 : 1068 1076.
14. Taylor MJ, Cross HF Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 2000 191 : 1429 1436.
15. Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG Piessens WF. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 1999 93 : 413 417.
16. Olszewski WL, Jamal S, Manokaran G, et al. Bacteriologic studies of skin, tissue fluid, lymph, and lymph nodes in patients with filarial lymphedema. Am J Trop Med Hyg 1997 57 : 7 15.
17. Olszewski WL, Jamal S, Manokaran G, Tripathi FM, Zaleska M Stelmach E. The effectiveness of long-acting penicillin (penidur) in preventing recurrences of dermatolymphangioadenitis(DLA) and controlling skin, deep tissues, and lymph bacterial flora in patients with "filarial" lymphedema. Lymphology 2005 38 : 66 80.
18. Debrah AY, Mand S, Toliat MR, et al. Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 2007 77 : 601 608.
19. Rajan TV. Neonatal tolerance and patent filarial infection. Trends Parasitol 2007 23 : 459 462.
20. Partono F. The spectrum of disease in lymphatic filariasis. Ciba Found Symp 1987 127 : 15 31.
21. Steel C, Guinea A, McCarthy JS Ottesen EA. Long-term effect of prenatal exposure to maternal microfilaraemia on immune responsiveness to filarial parasite antigens. Lancet 1994 343 : 890 893.
22. Malhotra I, Mungai PL, Wamachi AN, et al. Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. J Infect Dis 2006 193 : 1005 1013.
23. Nutman TB Kumaraswami V. Regulation of the immune response in lymphatic filariasis: perspectives on acute and chronic infection with Wuchereria bancrofti in South India. Parasite Immunol 2001 23 : 389 399.
24. Babu S, Bhat S, Kumar P, Kolappan C, Kumaraswami V Nutman TB. Filarial lymphatic pathology is characterized by augmented pro-inflammatory cytokine production in response to TLR2 and TLR9 ligands. In American Society of Tropical Medicine and Hygiene, 57th Annual Meeting, New Orleans, LA, USA. Am J Trop Med Hyg 2008 381 : 112.
25. Satoguina JS, Weyand E, Larbi J Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol 2005 174 : 4718 4726.
26. Satapathy AK, Sartono E, Sahoo PK, et al. Human bancroftian filariasis: immunological markers of morbidity and infection. Microbes Infect 2006 8 : 2414 2423.
27. Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006 42 : 1081 1089.
28. Taylor MJ, Cross HF, Ford L, Makunde WH, Prasad GB Bilo K. Wolbachia bacteria in filarial immunity and disease. Parasite Immunol 2001 23 : 401 409.
29. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995 92 : 3566 3570.
30. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001 7 : 199 205.
31. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001 20 : 1223 1231.
32. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998 95 : 548 553.
33. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998 95 : 14389 14394.
34. Korpelainen EI Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998 10 : 159 164.
35. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996 122 : 3829 3837.
36. Robinson CJ Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001 114 : 853 865.
37. Leung DW, Cachianes G, Kuang WJ, Goeddel DV Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 246 : 1306 1309.
38. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998 111 : 1 6.
39. Jussila L Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002 82 : 673 700.
40. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997 276 : 1423 1425.
41. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996 15 : 1751.
42. Numasaki M, Lotze MT Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004 93 : 39 43.
43. Asano-Kato N, Fukagawa K, Okada N, et al. TGF-beta1, IL-1 beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp Eye Res 2005 80 : 555 560.
44. Ristimaki A, Narko K, Enholm B, Joukov V Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem 1998 273 : 8413 8418.
45. McLaren DJ, Worms MJ, Laurence BR Simpson MG. Micro-organisms in filarial larvae (Nematoda). Trans R Soc Trop Med Hyg 1975 69 : 509 514.
46. Kozek WJ. Transovarially-transmitted intracellular microorganisms in adult and larval stages of Brugia malayi. J Parasitol 1977 63 : 992 1000.
47. Hoerauf A, Mand S, Adjei O, Fleischer B Büttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001 357 : 1415 1416.
48. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000 355 : 1242 1243.
49. Taylor M Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today 1999 15 : 437 442.
50. Büttner DW, Wanji S, Bazzocchi C, Bain O Fischer P. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa. Filaria J 2003 2 : 10.
51. McGarry HF, Pfarr K, Egerton G, et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J 2003 2 : 9.
52. Langworthy S, Renz A, Mackenstedt U, et al. Macrofilaricidal activity of tetracycline against the filarial nematode, Onchocerca ochengi: elimination of Wolbachia preceeds worm death and suggests a dependent relationship. Proc R Soc London Ser B 2000 267 : 1063 1069.
53. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008 197 : 295 311.
54. Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health 2007 12 : 1433 1441.
55. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S Hoerauf A. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005 365 : 2116 2121.
56. St. André A, Blackwell NM, Hall LR, et al. A critical role for endosymbiotic Wolbachia bacteria and TLR4 signaling in the pathogenesis of river blindness. Science 2002 295 : 1892 1895.
57. Cho ML, Ju JH, Kim HR, et al. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol Lett 2007 108 : 121 128.
58. Esterre P, Plichart C, Huin-Blondey MO Nguyen LN. Soluble cellular adhesion molecules, selectins, VEGF and endothelin-1 in patients with Wuchereria bancrofti infection and association with clinical status. Parasite Immunol 2005 27 : 9 16.
59. Dreyer G, Addiss D, Dreyer P Noroes J. Basic Lymphoedema Management. Treatment and Prevention of Problems Associated with Lymphatic Filariasis. Hollis, NH, Hollis Publishing Company, 2002.
60. Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg 2009 80 : 956 963.
61. Faris R, Hussain O, El Setouhy M, Ramzy RM Weil GJ. Bancroftian filariasis in Egypt: visualization of adult worms and subclinical lymphatic pathology by scrotal ultrasound. Am J Trop Med Hyg 1998 59 : 864 867.
62. Horii Y, Nakanishi H, Mori A, et al. Eosinophil hyporesponse of jirds induced by microfilariae of Brugia pahangi. Am J Trop Med Hyg 1989 41 : 183 188.
63. Babu S, Blauvelt CP, Kumaraswami V Nutman TB. Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J Immunol 2006 176 : 3248 3256.
64. King CL, Mahanty S, Kumaraswami V, et al. Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset. J Clin Invest 1993 92 : 1667 1673.
65. Ravichandran M, Mahanty S, Kumaraswami V, Nutman TB Jayaraman K. Elevated IL-10 mRNA expression and downregulation of Th1-type cytokines in microfilaraemic individuals with Wuchereria bancrofti infection. Parasite Immunol 1997 19 : 69 77.
66. Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008 46 : 1385 1393.
67. Ottesen EA, Mendell NR, MacQueen JM, Weller PF, Amos DB Ward FE. Familial predisposition to filarial infection - not linked to HLA-A or-B locus specificities. Acta Trop 1981 38 : 205 216.
68. Walter SD. On the detection of household aggregation of disease. Biometrics 1974 30 : 525 538.
69. Terhell AJ, Houwing-Duistermaat JJ, Ruiterman Y, Haarbrink M, Abadi K Yazdanbakhsh M. Clustering of Brugia malayi infection in a community in South-Sulawesi, Indonesia. Parasitology 2000 120 (Pt 1 23 29.
70. Wahyuni S, Houwing-Duistermaat JJ, Syafruddin, Supali T, Yazdanbakhsh M Sartono E. Clustering of filarial infection in an age-graded study: genetic, household and environmental influences. Parasitology 2004 128 : 315 321.
71. Cuenco KT, Halloran ME Lammie PJ. Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004 70 : 185 190.
72. Cuenco KT, Halloran ME, Louis-Charles J Lammie PJ. A family study of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004 70 : 180 184.
73. Choi EH, Zimmerman PA, Foster CB, et al. Genetic polymorphisms in molecules of innate immunity and susceptibility to infection with Wuchereria bancrofti in South India. Genes Immun 2001 2 : 248 253.
74. Hise AG, Hazlett FE, Bockarie MJ, Zimmerman PA, Tisch DJ Kazura JW. Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. Genes Immun 2003 4 : 524 527.
75. Radhakrishnan K Rockson SG. The clinical spectrum of lymphatic disease. Ann NY Acad Sci 2008 1131 : 155 184.
76. Fainaru O, Adini I, Benny O, et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J 2008 22 : 3728 3735.